Status:
COMPLETED
Oral Progesterone for Prevention of Preterm Birth
Lead Sponsor:
Fetal Medicine Foundation
Conditions:
Preterm Birth
Eligibility:
FEMALE
18-45 years
Phase:
PHASE3
Brief Summary
To evaluate whether daily oral micronized progesterone is effective in preventing recurrent spontaneous preterm birth (RSPB) and whether micronized progesterone use increases maternal serum progestero...
Detailed Description
To evaluate whether 400 mg daily oral micronized progesterone from 16 to 34 weeks' is effective in preventing recurrent spontaneous preterm birth (RSPB) and whether micronized progesterone use increas...
Eligibility Criteria
Inclusion
- pregnant women less than 20 weeks' gestation who had at least one prior spontaneous preterm birth of a liveborn baby between 20 \& 0/7 weeks' and 36 \& 6/7 weeks' gestation.
Exclusion
- multiple gestations, the presence of major fetal anomalies, progesterone use in the current pregnancy (ongoing or past), the presence of a cervical cerclage, and the presence of a placenta previa.
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT01180296
Start Date
November 1 2006
End Date
January 1 2009
Last Update
February 18 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Miami Valley HospitaL
Dayton, Ohio, United States, 45409